Skip to main content

Table 1 PD-L1 immunohistochemistry assays for clinical application

From: Clinical applications of PD-L1 bioassays for cancer immunotherapy

Agent

Nivolumab

Pembrolizumab

Atezolizumab

Durvalumab

Antibody

28-8

22C3

SP142

SP263

Isotype and host species

Rabbit IgG

Mouse IgG

Rabbit IgG

Rabbit IgG

Binding site

Extracellular

Extracellular

Intracellular

Intracellular

Cell scored

Tumor cell

Tumor cell

Tumor cell

Tumor cell

Tumor stroma

Immune cell

Cutoffs

1, 5, or ≥10%

≥50% tumor cell

1, 5, or ≥10%

≥25%

≥1% stroma